tbuckley/cabot-search huggingface dataset:
1797P Efficacy and safety analysis of EP / EC regimen combined with first-line anlotinib hydrochloride in the treatment of extensive small cell lung cancer: Results from a phase II single-arm trial
Authors: T. Kong, L. Chen, F. Duan, L. Wang, X. Zhao, X. Hou, H. Zhou, W. Miao, L. Wang, S. Hu
Journal: Annals of Oncology (2020)
Response to ‘Correspondence on ‘Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells’’ by Wang and Niu
Authors: Pei He, Hong Zhu, Long-Fei Wu, Fei-Yan Deng, Shu-Feng Lei
Journal: Annals of the Rheumatic Diseases (2020)

We appreciate the interest and comments shown by Wang et al about our study in their letter.1 2 We would like to clarify and discuss some issues Wang et al indicated.

First, matching design is generally used in case–control studies to eliminate the interference of potential confounding factors. Ideally, the subjects are perfectly matched in case–control (1:R) groups. In our research design stage, we also planned the ratio (1:1) of case–control that is commonly used in genetic and/or epigenetic studies. However, several steps of quality control were adopted in DNA/RNA preparation and microarray experiment, and some subjects were excluded, which led to the mismatched numbers, even though the sample ratio was originally designed as 1:1. The mismatched sample probably introduced some confounding effects, but such effects would be excluded to the greatest extent through our multiomics integration, replication …
564P Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours
Authors: J.S. Wang, M.A. Barve, E.G. Chiorean, P. LoRusso, K.D. Courtney, D. Qi, J. Bullington, M. Sardone, J. Chen, C. Brooks, M. Hoberman, T.I. Mughal, T.M. Bauer
Journal: Annals of Oncology (2020)
1170P The prognostic role of DLL3 expression in high-grade gastroenteropancreatic neuroendocrine neoplasms
Authors: C. Liverani, A. Bongiovanni, L. Mercatali, F. Pieri, C. Spadazzi, G. Miserocchi, G. Di Menna, F. Foca, S. Ravaioli, M.R. Aprile, A. De vita, C. Cocchi, F. Recine, T. Ibrahim
Journal: Annals of Oncology (2020)
1863P Impact of systemic treatment versus best supportive care on survival in patients older than 80 years with cancer
Authors: A. Olivares Hernandez, R.A. Escala Cornejo, L. Figuero Pérez, M.D.R. Vidal Tocino, J. Claros Ampuero, E. Escalera Martín, Á. López Gutiérrez, E. Terán Brage, A. Amores Martín, C.A. Rodríguez Sáchez, B. Barrios Collado, I. Toribio García, J.P. Miramontes-González, J.J. Cruz Hernández
Journal: Annals of Oncology (2020)
Priadel: Experts urge government to intervene to keep lithium product on market
Authors: Gareth Iacobucci
Journal: BMJ (2020)

Clinicians and patients have urged the UK government to intervene to ensure that Priadel, a brand of lithium widely used to treat bipolar disorder, remains available to patients.

Priadel costs £4.02 (€4.4; $5) for a pack of 400 mg tablets, making it relatively cheap for the NHS. But Essential Pharma, which owns the rights to Priadel, has announced that it is withdrawing the brand in April 2021. At the same time the company has increased the price of the other main brand of the drug, Camcolit, which it also owns, to £48.18 per pack of 400 mg tablets.

In direct drug costs alone it is estimated the change will cost the NHS around £15m a year.

In a letter to England’s health and social care secretary, Matt Hancock, representatives of bodies including the Royal Pharmaceutical Society, the Royal College of General Practitioners, and the Royal College of Psychiatrists warned that the move would not only …
A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking
Authors: Emily B. Harrison, Alessandro Porrello, Brittany M. Bowman, Adam R. Belanger, Gabriella Yacovone, Salma H. Azam, Ian A. Windham, Subrata K. Ghosh, Menglin Wang, Nicholas Mckenzie, Trent A. Waugh, Amanda E.D. Van Swearingen, Stephanie M. Cohen, Devon G. Allen, Tyler J. Goodwin, Teresa Mascenik, James E. Bear, Sarah Cohen, Scott H. Randell, Pierre P. Massion, Michael B. Major, Leaf Huang, Chad V. Pecot
Journal: Cancer Research (2020)

Abstract Lung squamous carcinoma (LUSC) is a highly metastatic disease with a poor prognosis. Using an integrated screening approach, we found that miR-671-5p reduces LUSC metastasis by inhibiting a circular RNA (circRNA), CDR1as. Although the putative function of circRNA is through miRNA sponging, we found that miR-671-5p more potently silenced an axis of CDR1as and its antisense transcript, cerebellar degeneration related protein 1 (CDR1). Silencing of CDR1as or CDR1 significantly inhibited LUSC metastases and CDR1 was sufficient to promote migration and metastases. CDR1, which directly interacted with adaptor protein 1 (AP1) complex subunits and coatomer protein I (COPI) proteins, no longer promoted migration upon blockade of Golgi trafficking. Therapeutic inhibition of the CDR1as/CDR1 axis with miR-671-5p mimics reduced metastasis in vivo. This report demonstrates a novel role for CDR1 in promoting metastasis and Golgi trafficking. These findings reveal an miRNA/circRNA axis that regulates LUSC metastases through a previously unstudied protein, CDR1. Significance: This study shows that circRNA, CDR1as, promotes lung squamous migration, metastasis, and Golgi trafficking through its complimentary transcript, CDR1.
1901P Immunomodulatory role of multi-agent therapy in thymic epithelial tumours and severe immunological dysregulation
Authors: M. Ottaviano, M. Giuliano, M. Tortora, F. Picozzi, B. Mucci, S. Parola, V. Riccio, E. Pietroluongo, P. De Placido, A. Vaia, V. D'Esposito, A.M. Malfitano, S. Di Somma, S. Campione, S. Staibano, G. Botti, P. Formisano, B. Daniele, S. De Placido, G. Palmieri
Journal: Annals of Oncology (2020)
112P Impact of clinical parameters on CD8 and CD4 lymphocyte distribution in patients with non-small cell lung cancer (NSCLC)
Authors: T. Soria Comes, V. Palomar Abril, J. García Sánchez, M.D.C. Cancela Gomez, H. Elfau Mur, S. Pascual Solaz, M. Martin Ureste, J.E. Marco Buades, A. López Gabaldón, M. González Jurado, M.J. Fernández Llavador, I. Maestu Maiques
Journal: Annals of Oncology (2020)
96P Validation for clinical use of NGS-based assay to detect circulating tumor DNA (ctDNA) in patients (pts) with various types of cancer
Authors: M. Fedyanin, U. Boyarskikh, A. Kechin, E. Polyanskaya, V. Aliev, A. Polyakov, N. Kudashkin, A. Arzumanyan, O.O. Gordeeva, S. Bagrova, M. Tikhonovskaya, A. Trigolosov, D. Denchik, M. Nikulin, S. Nered, E. Moroz, A. Chekini, M. Filipenko, S. Tjulandin
Journal: Annals of Oncology (2020)
465P Single nucleotide polymorphism (SNP) analysis identifies potential prognostic and predictive biomarker in patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib in the phase III CORRECT trial
Authors: F. Battaglin, W. Zhang, A. Skubala, H. Arai, J. Wang, S. Soni, Y.A. Wang, K. Köchert, A. Schulz, M. Teufel, J. Millstein, H.J. Lenz
Journal: Annals of Oncology (2020)
695TiP ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to characterize the prostate cancer pathway, management and outcomes in Europe, Middle East and Africa (EMEA region)
Authors: J. Carles, A. Alcaraz, N.W. Clarke, A. Conde, A. Heidenreich, A. Juarez, J.P. Maroto Rey, J. Puente, I. Hernandez-Medrano, I. Salcedo, I. Haddad, J. Munoz del Toro, A. Servan, G. Pissart, J. Casariego, K. Fizazi
Journal: Annals of Oncology (2020)
1051P Clinical experience of tabelecleucel in patients with EBV+ primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease
Authors: S. Nikiforow, R. Baiocchi, S. Nasta, W. Weng, D. Loeb, K.M. Mahadeo, J. Whangbo, P. Phuong, W. Navarro, L. Gamelin, Y. Sun, N. Guzman-Becerra, S. Prockop
Journal: Annals of Oncology (2020)
367MO Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective, observational study
Authors: L. Gatto, A. Tosoni, E. Franceschi, V. Di Nunno, S. Minichillo, A. Mura, M. Di Battista, C. Lamperini, M. Mosca, G. Nuvola, M. Sisi, S. Bartolini, A.A. Brandes
Journal: Annals of Oncology (2020)
969P Comparison of outcomes of weekly paclitaxel versus weekly cisplatin in oral cavity, oropharyngeal and hypopharyngeal cancer patients with concurrent radiation: A randomized controlled trial
Authors: K. Durga Harika, V. Parthasarathy, K. Sri Harsha, V. Aswin Chandran, T. Joseph Rajiv, S. Shiva kumar
Journal: Annals of Oncology (2020)
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study
Authors: P. Giannatempo, D. Raggi, L. Marandino, M. Bandini, E. Farè, G. Calareso, M. Colecchia, A. Gallina, J.S. Ross, A. Alessi, A. Briganti, F. Montorsi, R. Madison, A. Necchi
Journal: Annals of Oncology (2020)
924P SNS-301 added to pembrolizumab in patients (Pts) with ASPH+ advanced squamous cell carcinoma of the head &amp; neck (SCCHN)
Authors: A.P. Algazi, M. Guarino, T.J. Panella, J. Celebi, I. Csiki, A. Drumheller, J. Campbell, R. Pierce, W.B. Smith
Journal: Annals of Oncology (2020)
752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
Authors: A.O. Siefker-Radtke, Y. Loriot, S. Siena, C. Beato, M.A. Climent Duran, S. Varlamov, I. Duran, S.T. Tagawa, L. Geoffrois, B. Mellado, A. Semenov, R. Delva, A.P. Lykov, L.Y. Dirix, S. Akapame, A. O'Hagan, M. Tammaro, S. Mosher, T.W. Kang, V. Moreno
Journal: Annals of Oncology (2020)
860P Redefining prognosis in early-stage high-grade endometrial cancer
Authors: J.L. Ramón, I. Ruz Carancuel, V. Heredia Soto, L.E. García de la Calle, Á. López Janeiro, F.J. Escudero, R. Crespo, P. Ruiz, M. Miguel, A. Berjón, A. Gallego Martínez, A. Hernández, A. Peláez-García, D. Hardisson, M. Mendiola, A. Redondo
Journal: Annals of Oncology (2020)
1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
Authors: R. Descourt, M. Pérol, D. Planchard, G. Rousseau-Bussac, B. Mennecier, M. Wislez, J. Cadranel, A.B. Cortot, F. Guisier, P. Do, R. Schott, E. Dansin, J. Arrondeau, J.B. Auliac, C. Chouaid, L. Galland
Journal: Annals of Oncology (2020)
1098P Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR: A prospective single arm phase II trial
Authors: M. Rohaan, S. Blankenstein, M. Klop, B. van der Hiel, M.J. Lahaye, A. Sari, K. Sikorska, B.A. van de Wiel, D. Peeper, A.C.J. van Akkooi, J.B.A.G. Haanen
Journal: Annals of Oncology (2020)
1212P Exosomes cargo analysis as an approach to identify new biomarkers in NSCLC
Authors: E. Duréndez Sáez, S. Calabuig-Fariñas, C. Suarez, M. Ferrero Gimeno, M. Mosqueda, A. Moreno, S. Torres Martinez, A. Hererros-Pomares, S. Gallach Garcia, M. Nunez Abad, A. Blasco Cordellat, F.D.A. Aparisi Aparisi, E. Serna, J.M. Paramio, E. Jantus Lewintre, C. Camps
Journal: Annals of Oncology (2020)
508P Evaluating colorectal cancer treatment patterns by stage in European cancer registries
Authors: F. Giusti, C. Martos, L. Neamtiu, G. Randi, T.A. Dyba, M. Flego, R. Carvalho, N. Dimitrova, N. Nicholson, M. Bettio
Journal: Annals of Oncology (2020)
Opsoclonus in Anti-Ma2 Brain-Stem Encephalitis
Authors: Amy Kunchok, Andrew McKeon
Journal: New England Journal of Medicine (2020)

A 71-year-old man presented with a 3-month history of vertigo, diplopia, and ataxia. He had rapid, nonrhythmic, saccadic, and multidirectional ocular movements (shown in a video), a condition known as opsoclonus. Serum was positive for Ma2 IgG antibodies.
779P Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials
Authors: O. Alhalabi, A.W. Hahn, P. Msaouel, F. Meric-Bernstam, A. Naing, S. Piha-Paul, F. Janku, S. Pant, T.A. Yap, D.S. Hong, S. Fu, D.D. Karp, E. Campbell, M.T. Campbell, A.Y. Shah, N. Tannir, A.O. Siefker-Radtke, J. Gao, J. Roszik, V. Subbiah
Journal: Annals of Oncology (2020)
419P Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay
Authors: A. Parikh, E. van Seventer, G. Boland, G. Siravegna, A. Hartwig, A. Jaimovich, V.M. Raymond, A. Talasaz, R.B. Corcoran
Journal: Annals of Oncology (2020)
544P Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours
Authors: C. Morizane, T. Kojima, Y. Kuboki, H. Bando, N. Matsubara, K. Shitara, K. Yoh, H. Hirai, T. Kato, T. Doi
Journal: Annals of Oncology (2020)
Intraocular lenses: Antibacterial Nanopillar Array for an Implantable Intraocular Lens (Adv. Healthcare Mater. 18/2020)
Authors: Goro Choi, Younseong Song, Hyungjun Lim, Song Ha Lee, Hyung Keun Lee, Eunjung Lee, Bong Gill Choi, Jae Jong Lee, Sung Gap Im, Kyoung G. Lee
Journal: Advanced Healthcare Materials (2020)

In article 2000447 by Sung Gap Im, Kyoung G. Lee and co-workers, a novel approach is provided for the monolithic antibacterial functionalization of an intraocular lens (IOL) using an ionic polymer-coated nanopillar array (NPA). The ionic polymer-coated NPA exhibits excellent antibacterial performance through rupturing and destabilizing the bacterial membrane. The proposed strategy can prevent potential bacterial infection and IOL replacement after a cataract surgery.
Synthesis and preliminary studies of <sup>11</sup>C-labeled tetrahydro-1,7-naphthyridine-2-carboxamides for PET imaging of metabotropic glutamate receptor 2
Authors: Xiaofei Zhang, Yiding Zhang, Zhen Chen, Tuo Shao, Richard Van, Katsushi Kumata, Xiaoyun Deng, Hualong Fu, Tomoteru Yamasaki, Jian Rong, Kuan Hu, Akiko Hatori, Lin Xie, Qingzhen Yu, Weijian Ye, Hao Xu, Douglas J Sheffler, Nicholas D P Cosford, Yihan Shao, Pingping Tang, Lu Wang, Ming-Rong Zhang, Steven H Liang
Journal: Theranostics (2020)

Selective modulation of metabotropic glutamate receptor 2 (mGlu2) represents a novel therapeutic approach for treating brain disorders, including schizophrenia, depression, Parkinson's disease (PD), Alzheimer's disease (AD), drug abuse and addiction. Imaging mGlu2 using positron emission tomography (PET) would allow for in vivo quantification under physiological and pathological conditions and facilitate drug discovery by enabling target engagement studies. In this paper, we aimed to develop a novel specific radioligand derived from negative allosteric modulators (NAMs) for PET imaging of mGlu2. Methods. A focused small molecule library of mGlu2 NAMs with tetrahydro naphthyridine scaffold was synthesized for pharmacology and physicochemical evaluation. GIRK dose-response assays and CNS panel binding selectivity assays were performed to study the affinity and selectivity of mGlu2 NAMs, among which compounds 14a and 14b were selected as PET ligand candidates. Autoradiography in SD rat brain sections was used to confirm the in vitro binding specificity and selectivity of [11C]14a and [11C]14b towards mGlu2. In vivo binding specificity was then studied by PET imaging. Whole body biodistribution study and radiometabolite analysis were conducted to demonstrate the pharmacokinetic properties of [11C]14b as most promising PET mGlu2 PET ligand. Results. mGlu2 NAMs 14a-14g were synthesized in 14%-20% yields in five steps. NAMs 14a and 14b were selected to be the most promising ligands due to their high affinity in GIRK dose-response assays. [11C]14a and [11C]14b displayed similar heterogeneous distribution by autoradiography, consistent with mGlu2 expression in the brain. While PET imaging study showed good brain permeability for both tracers, compound [11C]14b demonstrated superior binding specificity compared to [11C]14a. Further radiometabolite analysis of [11C]14b showed excellent stability in the brain. Conclusions. Compound 14b exhibited high affinity and excellent subtype selectivity, which was then evaluated by in vitro autoradiography and in vivo PET imaging study after labeling with carbon-11. Ligand [11C]14b, which we named [11C]MG2-1904, demonstrated high brain uptake and excellent in vitro/in vivo specific binding towards mGlu2 with high metabolic stability in the brain. As proof-of-concept, our preliminary work demonstrated a successful example of visualizing mGlu2in vivo derived from NAMs, which represents a promising chemotype for further development and optimization aimed for clinical translation.
156P High TLR3 expression predicts improved survival in patients with clear cell renal cell carcinoma
Authors: M. Li, Z. Li, P. Kalinski, C. Verschraegen, S. Clinton, Y. Yang, A. Mortazavi, P. Monk, E. Folefac, M. Yin, A. Parikh, Y. Yang
Journal: Annals of Oncology (2020)
1853P Real-world evidence of quality of life effects (QoL) of the antiemetic NEPA: Final data in patients receiving oxaliplatin-based chemotherapy within the AkyPRO-trial
Authors: M. Karthaus, M.K. Welslau, N. Gazawi, M. Neise, J. Rauh, B. Whitlock, V. Boheme, M. Grunewald, J. Schilling
Journal: Annals of Oncology (2020)
895P Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma
Authors: Y-K. Shi, Y. Song, Y. Qin, K. Zhou, Y. Gao, M. Wang, P. Wang, Q. Yin, F. Zhao, G. Ma, F. Li
Journal: Annals of Oncology (2020)
Correction: A case of severe hepatolithiasis after hepaticojejunostomy with Roux-en-Y reconstruction treated by endoscopic ultrasound-guided transhepatic antegrade stone removal
Authors: Toshihiro Homma, Kenjiro Yamamoto, Takayoshi Tsuchiya, Ryosuke Tonozuka, Hirohito Minami, Eri Joyama, Takao Itoi
Journal: Endoscopy (2020)

Correction to: A case of severe hepatolithiasis after hepaticojejunostomy with Roux-en-Y reconstruction treated by endoscopic ultrasound-guided transhepatic antegrade stone removalEndoscopy 2021; 53(06): E230-E231DOI: 10.1055/a-1244-9556
1354P Detection of EGFR T790M in EGFR activating mutation-positive advanced non-small cell lung cancer (NSCLC): Comparison between two assays on circulating tumour (ct)DNA
Authors: S. Charpentier, G. Herbreteau, A. Vallée, D. Henaff, L. Grewis, M.G. Denis
Journal: Annals of Oncology (2020)
326P Exploratory analysis of TreatER+ight: A Canadian prospective real-world observational study in HR+ advanced breast cancer
Authors: C. Doyle, T.A. Vandenberg, C. Ferrario, N. Califaretti, N.N. Iqbal, S. Kulkarni, M. Mates, J. Hilton, N. Bouganim, J-W. Henning, S. Haftchenary, S.R. Perri, S.K.L. Chia
Journal: Annals of Oncology (2020)
Emerging medical therapies for severe alcoholic hepatitis
Authors: David Tornai, Gyongyi Szabo
Journal: Clinical and Molecular Hepatology (2020)

Severe alcoholic hepatitis (AH) is an acute and often devastating form of alcohol-associated liver disease. Clinically, AH is characterized by elevated bilirubin, model for end stage liver disease scores &gt;20, and nonspecific symptoms that are caused by underlying inflammation, hepatocyte injury, and impaired intestinal barrier function. Compromised immune defense in AH contributes to infections, sepsis and organ failure. To date, corticosteroids are the only recommended treatment for severe AH, however it does not provide survival benefits beyond 1 month. Recent preclinical and early clinical studies in AH aided understanding of the disease and presented opportunities for new therapeutic options targeting inflammation, oxidative stress, liver regeneration and modification of intestinal microbiota. In this comprehensive review, we discuss promising preclinical results and ongoing clinical trials evaluating novel therapeutic agents for the treatment of severe AH.
Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’
Authors: Lara Fallon, Thomas V Jones
Journal: Annals of the Rheumatic Diseases (2020)

We read with interest the recently published European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis (PsA) with pharmacological therapies1 and the associated systematic literature research (SLR)2; we welcome the clarity that they offer for patient care.

We would like to bring three points to your readers’ attention to correct and clarify the narrative supporting Recommendation 7 (Janus kinase (JAK) inhibitors).

Recommendation 7 states: “ … Our SLR indicated tofacitinib may have similar efficacy as the TNFi adalimumab for joint involvement, but numerically lower efficacy in skin psoriasis.1,15,72 … Safety signals exist for some infections, especially herpes zoster, as well as a recent signal for deep vein thrombosis especially with a high dose of tofacitinib which is not approved for PsA, but also the usual 5 mg twice daily dose particularly in those with cardiovascular risk factors and older patients.15,72,73”

Regarding the statement: “ … as well as a recent signal for deep vein thrombosis especially with a high dose of tofacitinib which is not approved for PsA …”:

We would like to respectfully correct this statement, as this signal was seen for pulmonary embolism (PE) rather than deep vein thrombosis (DVT); this was observed in the 10 mg twice daily dose of tofacitinib, …
1790P Clinical utility of ctDNA and CTCs for genomic profiling and monitoring chemotherapy response in patients with small cell lung cancer
Authors: Y. Feng, X. Hu, T. Zhang, L. Zhang, G. Dong, M. Yuan, H. Zhu, Y. Liu, P. Xing, H. Wang, B. Li, Y-K. Shi
Journal: Annals of Oncology (2020)
282MO Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer (GAP): A multicenter, randomized, open-label, phase III trial
Authors: X. Hu, B. Wang, J. Zhang, Z. Wang, T. Sun, S. Wang, Y. Teng, M. Yan, X. Wang, Z. Jiang, L. Cai, Y. Pan
Journal: Annals of Oncology (2020)
1402P Epidermal growth factor receptor mutation (EGFRm) testing in advanced non-small cell lung cancer (aNSCLC) in a real-world setting
Authors: J. Subramanian, J. Gregg, H. Wang, P. Sun, B. Yu, R. Shenolikar, M. Chau, A. Taylor, N. Leighl
Journal: Annals of Oncology (2020)
1834P Febrile neutropenia outside of clinical trials in intermediate-risk patients receiving chemotherapy: A MASCC neutropenia, infection and myelosuppression study group-prospective, real-world study
Authors: L. Heyman, M. Garcia-Morillo, M. Paesmans, J.G. Gomez, C. Font, Z. Samoon, H.R. Kourie, R. Popescu, A. Kayumba, A.A. Jabbar, F. Esposito, N. Mathieson, A. Krendyukov, J.A. Klastersky, B.L. Rapoport
Journal: Annals of Oncology (2020)
1858P Role of depression and quality of life (QOL) status as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts)
Authors: O. Mirallas, D.E. López Valbuena, M.A. Rezqallah Aron, G. Molina, S. Vega, D. Gómez-Puerto, G. Villacampa Javierre, L. Andurell, F. Palmas, R. Burgos, K. Rodriguez, I. Moreno, M.J. Delgado Heredia, M. Roca, R. Dienstmann, A. Alonso, S. Serradell, J. Carles
Journal: Annals of Oncology (2020)
848P Features and clinical outcomes for younger women with epithelial ovarian cancer (EOC)
Authors: E. Colomba-Blameble, P. Pautier, J. Michels, F. Pommeret, M. Kfoury, A. Maulard, S. Gouy, P. Morice, C. Genestie, A. Leary
Journal: Annals of Oncology (2020)
645P Prediction of BRCA2 mutations in prostate cancer patients according early onset, metastatic phenotypes or family history of breast/ovary cancer
Authors: G. Cancel-Tassin, P. Leon, V. Bourdon, B. Buecher, S. Oudard, L. Brureau, L. Jouffe, P. Blanchet, D. Stoppa-Lyonnet, F. Coulet, H.H. Sobol, O. Cussenot
Journal: Annals of Oncology (2020)